Cardiovascular Safety and Superiority of Anti-Obesity Medications
Muath Alobaida,1,* Abdullah Alrumayh,1,* Ayodipupo S Oguntade,2 Faez Al-Amodi,3 Mwango Bwalya3 1Department of Basic Sciences, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi Arabia; 2Nuffield Department of Population...
Guardado en:
Autores principales: | Alobaida M, Alrumayh A, Oguntade AS, Al-Amodi F, Bwalya M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5146ded483e84cf48f6788278e5f7e76 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis
por: Huang H, et al.
Publicado: (2018) -
Prevalencia de factores de riesgo de enfermedad cardiovascular en una población de empleados chilenos
por: Lanas Z,Fernando, et al.
Publicado: (2003) -
Obesity and morbid obesity associated with higher odds of hypoalbuminemia in adults without liver disease or renal failure
por: Mosli RH, et al.
Publicado: (2017) -
Menopausia y factores de riesgo cardiovascular en mujeres chilenas
por: Martorell,Miquel, et al.
Publicado: (2020) -
Pattern of Obesity Among Patients with Type 2 Diabetes at a Tertiary Healthcare Center in Northern Nigeria
por: Gezawa ID, et al.
Publicado: (2019)